RxDoctor Payments Data

Julie Dyrek, APRN

Psychiatric/Mental Health · Lake Charles, LANPI 1427668748

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,800, 2.5 times the $1,112 reported in 2021. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,875in general payments, 2019–2025

Across 218 payments — averaging $36.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$777
  • Otsuka America Pharmaceutical, Inc.$722
  • Teva Pharmaceuticals USA, Inc.$587
  • E.r. Squibb & Sons, L.L.C.$336
  • plus $3K from 14 others

What the payments were for

  • Food & beverage$7,77599%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,875 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$23,108
Medicare patients
41
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Divalproex Sodium19$287
Gabapentin21$234
Quetiapine Fumarate15$198
Prazosin Hcl17$180
Mirtazapine17$159
Buspirone Hcl20$152
Aripiprazole15$150
Duloxetine Hcl19$137
Trazodone Hcl19$133
Olanzapine14$131
Atorvastatin Calcium22$119
Benztropine Mesylate12$117
Amlodipine Besylate20$85
Metformin Hcl12$38
Escitalopram Oxalate15$36

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →